Immunostimulatory chimeric protein encapsulated in gelatin nanoparticles elicits protective immunity against Pseudomonas aeruginosa respiratory tract infection.

Autor: Parvaei M; Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran., Habibi M; Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran., Shahbazi S; Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran., Babaluei M; National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran., Farokhi M; National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran. Electronic address: m_farokhi@pasteur.ac.ir., Asadi Karam MR; Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran. Electronic address: m_asadi@pasteur.ac.ir.
Jazyk: angličtina
Zdroj: International journal of biological macromolecules [Int J Biol Macromol] 2024 Oct; Vol. 277 (Pt 1), pp. 133964. Date of Electronic Publication: 2024 Jul 17.
DOI: 10.1016/j.ijbiomac.2024.133964
Abstrakt: This study presents the design and fabrication of an innovative vaccine candidate targeting Pseudomonas aeruginosa (P. aeruginosa). The vaccine consists of gelatin nanoparticles (GNPs) encapsulating a chimeric protein (CP) derived from the ExoS and OprI proteins from P. aeruginosa. The physicochemical properties of the GNPs were assessed using dynamic light scattering (DLS) and electron microscopy. The toxicity, encapsulation efficacy, release profile, and effectiveness of CP-encapsulated GNPs (CP-GNPs) in an animal model were investigated. The resulting nanovaccine demonstrated uniform spherical particles with an average size of 135 nm and an encapsulation efficiency of 85 %. The release assay revealed that 23 % of the antigen was released from the CP-GNPs after 20 days. The GNPs did not exhibit any toxic effects on L929 cells in vitro. The formulation induced both systemic and mucosal antibody responses. Additionally, CP-GNPs stimulated cytokine responses, including IFN-γ, IL-4, and IL-17, indicating the induction of both humoral (Th2) and cellular (Th1) responses. The CP-encapsulated GNPs formulation effectively protected the mice lungs against experimental respiratory tract infection, reducing colony count and inflammation. These findings suggest that CP-GNPs hold promise as a potential strategy for preventing respiratory tract infections caused by P. aeruginosa. Further research is needed to explore its clinical application.
Competing Interests: Declaration of competing interest The authors declare that there are no identifiable conflicting financial interests or personal relationships that could potentially have influenced the findings presented in this paper.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: